SCHEMBL2925592

SCHEMBL2925592

CS(=O)(=O)c1ccc2c(c1)cc(-c1nnco1)n2S(=O)(=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.42
CA9 Q16790 3/20 0.42
CA2 P00918 1/20 0.42
POLB P06746 1/20 0.37
BRD4 O60885 1/20 0.37
TP53 P04637 2/20 0.36
ACLY P53396 1/20 0.36
PPARG P37231 3/20 0.35
PPARA Q07869 3/20 0.35
GAA P10253 2/20 0.35
PKM P14618 2/20 0.35
RECQL P46063 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NOTUM Q6P988 1/20 0.35
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
PPARD Q03181 1/20 0.34
ATP4A P20648 2/20 0.34
ATP4B P51164 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2925579 0.86 HTR6 (0.40) CA12CA9CA2POLBBRD4
SCHEMBL2925451 0.74 CA12 (0.48) CA12CA9CA2ACLY
SCHEMBL2925335 0.72 PTGS2 (0.56) NOTUMMAPK1NPC1TSHRRAB9A
SCHEMBL2929576 0.72 CA12 (0.41) CA12CA9CA2ACLYPPARG
SCHEMBL2928475 0.68 PTGS2 (0.55) PPARGPPARALMNANOD1
SCHEMBL2929578 0.67 PRKDC (0.40) CA12CA9CA2POLBACLY
SCHEMBL2930203 0.66 NOD2 (0.46) ACLYPPARGPPARAGAASMN1; SMN2
SCHEMBL2927024 0.66 GBA1 (0.36) CA12CA9CA2RECQLLMNA
SCHEMBL2930588 0.66 PTGS1 (0.38) CA12CA9CA2PPARGPPARA
SCHEMBL3560088 0.66 ACLY (0.63) CA12CA9CA2ACLYPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1086950-B1 HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-09-29 EP disclosed
US-7612070-B2 Heterocyclic compounds as antiinflammatory agents and cyclooxygenase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-11-03 US disclosed
US-20050137202-A1 Indole derivative having heterocycle and mono- or diazaindole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-06-23 US disclosed
US-6875770-B2 Indole derivative having heterocycle and mono- or diazaindole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-04-05 US disclosed
US-20040067964-A1 Indole derivative having heterocycle and mono- or diazaindole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-04-08 US disclosed
US-6673797-B1 CYCLOOXYGENASE-2 INHIBITORS; TREATING INFLAMMATORY DISEASE INDUCED BY CYCLOOXYGENASE-2 CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-01-06 US disclosed
EP-1086950-A1 HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137202-A1 Indole derivative having heterocycle and mono- or diazaindole derivative PTGS2, IDO2, IDO1 CA12 1222/4885CA9 396/4885CA2 101/4885
US-20040067964-A1 Indole derivative having heterocycle and mono- or diazaindole derivative IDO1, PTGS1, IDO2 CA12 2770/4885CA9 587/4885CA2 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.